Member Info for Money_Hoarder_95

Typical this rockets up over 3.50% the day before we can reinvest our dividends.

Barclays knocking 90p off their target price to £5.85 is understandable, but Berenberg knocking £1.60 off their target price to now £3.20 a share is way too negative despite the current circumstances concerning the EPL. Perhaps a typo? Or perhaps some Berenberg's client(s) are shorting?

lol at LSE censoring his surname.

This was inevitable when they decided to spend £37bn on NHS Track and Fraud... ahem... Trace. Now we are all paying the price through draconian tax hikes.

Brent up 2.5%.

RNS Buy Back OUT!!!

08-Nov-22 11:39:39 218.50 100,000 Buy* 210.00 220.00 218.50k O
08-Nov-22 11:37:07 217.50 150,000 Buy* 210.00 220.00 326.25k O

Nice to see.

*Placing took place in September not October, however on the director deals section, it says the 3rd of October.

Crazy at this price considering the 265p placing last month. Bought in.

SINGAPORE (Reuters) - HSBC reported on Tuesday a drop of 42% in third-quarter profit, on the back of rising credit loss provisions and other impairments, but its net interest income surged as banks benefit from rising interest rates.

The London-headquartered lender posted a pretax profit of $3.15 billion for the three months ended Sept. 30, down from $5.4 billion a year ago, compared with the $2.45 billion average of analyst estimates compiled by the bank.

The results included an impairment of $2.4 billion, following reclassification of the bank’s retail operations in France to be held for sale.

The trading statement on the 9th September said:

“ASOS will report full-year results on 12 October 2022.”

"... I bought my first house in 1994 in Bath, 3 bedroom terrace for 65k. The same street now sells for 600k. With hindsight I’d have bought the street."

All can be explained when you look at chart (choose MAX which starts just before 1988) on the UK M2 Money supply:

https://tradingeconomics.com/united-kingdom/money-supply-m2

Goldman Sachs cuts Schroders price target to 2,620 (2,680) pence - 'sell'
----------
Goldman Sachs cuts Abrdn price target to 180 (190) pence - 'neutral'

How can they put a neutral call on Abrdn, an asset manager that's struggling with huge outflows and put a sell call on Schroders, a well run asset manager that's grew AUM from H1'21 £734.1bn to H1'22 £773.4bn (I think part of the growth in AUM was Schroders' 75% stake acquisition of Greencoat Capital.)

I understand in this current market environment, why Schroders isn't a buy as inevitably AUM will be down when they report results next year but why do Goldman Sachs favour Abrdn over Schroders?

from 2.975291% to 3.110990%

It's crazy how Arix Bioscience isn't trading in the range of 130p - 140p, considering Arix has 100p per share in cash alone. You nearly get a free ride on the portfolio.

There's always gonna be a large discount to NAV because of how risky PE and listed biotech companies are, but this wide discount is unjustified.

Financial Highlights

Net Asset Value of £228 million (31 December 2021: £255 million); 176p per share (31 December 2021: 198p)

Net downward portfolio movement of £25.0 million in the period, primarily driven by the reduction in the value of our core public company holdings, which have been affected by the significant decline in the public biotech markets

Gross Portfolio Value of £93.9 million (31 December 2021: £118.2 million)

Healthy cash position at period-end of £131.1 million (31 December 2021: £134.2 million)

"So, tomorrow it is then ...."

And the RNS will be released at the very last minute.

Lloyds just bought Embark Group last year for £400m and are also building their Landlord business, Citra. I don't see them being contenders to purchase Quilter, but who knows? Anything can happen.

My guess:

7p per share + £1bn share buyback

(Probably gonna be nowhere near this :))

26-Jul-22 15:09:09 40.00 303,847 Buy* 39.00 40.00 121.54k O

Nice to see a big buy.